Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Structure Therapeutics has a long way to go before beating Wegovy.
With weight-loss drugs gaining traction, which biopharma stock wins?
Structure Therapeutics is a clinical-stage weight-loss company that is poised to gain traction in a rapidly expanding addressable market.
Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.
It has genuine struggles ahead, but it has some actual value in hand as well.
These two biotechs have important catalysts coming up in December.
Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them.